Longleaf Partners, managed by Southeastern Asset Management, released its “Partners Fund” second-quarter 2025 investor letter. A copy of the letter can be downloaded here.

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

Key Points From the end of June through July 10, shares of ProKidney Corp. shot 775% higher.ProKidney is developing a ...

Shares of Regeneron Pharmaceuticals, Inc. REGN have lost 22.6% year to date against the industry’s growth of 0.6%. The stock ...

After strong multi-year performance in Financials, Dodge & Cox Global Stock Fund continued to steadily reduce its overweight position in the sector. Read more here.

GE Vernova stock price surged to a record high after the company published strong financial results and forward guidance.

Sanofi's wide lineup of branded drugs and vaccines and robust pipeline create strong cash flows and a narrow economic moat. Growth of existing products and new product launches should help offset ...

In addition to evaluating these valuations against the benchmark, it is also helpful to compare them to each other. In a ...

Morse Asset Management Inc has significantly increased its stake in Regeneron Pharmaceuticals, boosting its share count by a ...

The atopic dermatitis market, valued at USD 9.33 billion in 2024, is projected to grow at a CAGR of 15.10%, reaching USD 38.07 billion by 2034. Key d ...

WALL Street’s concentration in the red-hot tech sector is, by some measures, greater than it has ever been, eclipsing levels hit during the 1990s dotcom bubble. But does this mean history is bound to ...

Amgen's share price saw a 22% rise over three years, lagging behind the broader market's returns. During this period, Amgen's ...